← All Signals

🏥 FDA: K.C. Pharmaceuticals, Inc — Class II

healthcareactionableSource: FDA
92%Confidence
0Views
FDASource
2026-04-14Date

Summary

Sterility concerns extend to K.C. Pharmaceuticals' tetrahydrozoline eye drops, affecting both Perrigo and Walgreens private label products. This pattern suggests facility-wide contamination issues that could lead to FDA enforcement actions.

Actionable: Suspend sales of all K.C. Pharmaceuticals manufactured eye drops and implement enhanced quality checks for similar products.

AI Confidence: 92%

Data Points

firmK.C. Pharmaceuticals, Inc
classificationClass II
statusOngoing
distributionNationwide in the US
productSterile Eye Drops ORIGINAL FORMULA (tetrahydrozoline HCl 0.05%), 0.5 FL OZ (15mL) bottles; a) Good Sense Sterile Eye Drops, Distributed By: Perrigo Di

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now